Type
Business expansion
Country
Austria
Region
Westösterreich; Tirol;
Location of affected unit(s)
Schaftenau
Sector
Manufacturing
Manufacture Of Chemicals And Pharamceuticals
Manufacture Of Basic Pharmaceutical Products And Pharmaceutical Preparations
21 - Manufacture of basic pharmaceutical products and pharmaceutical preparations

190 jobs
Number of planned job creations
Job creation
Announcement Date
3 November 2017
Employment effect (start)
7 November 2017
Foreseen end date

Description

The Swiss-based pharmaceutical enterprise Novartis will invest €100 million in a new production site in Tyrol, Austria, creating 190 new jobs. According to the company, a high global demand for pharmaceutical products requires the expansion of the Schaftenau site in Tyrol, which will include a cell culture production site as well as office buildings. The Schaftenau site produces bio-pharmaceuticals (biologicals) for Novartis and biosimilars for Novartis subsidiary Sandoz for the global market. Biologicals are considered the future in medical treatment.

As of 2017, Novartis employs 5,100 people in Austria.


Sources

  • 3 November 2017: Die Presse
  • 3 November 2017: Der Standard
  • 3 November 2017: ORF Tirol online

Citation

Eurofound (2017), Novartis, Business expansion in Austria, factsheet number 92443, European Restructuring Monitor. Dublin, https://restructuringeventsprod.azurewebsites.net/restructuring-events/detail/92443.